When two or more
medicines are taken together, it can change how the medicines work and increase the risk of side-effects. In medical terms, this is called as a
Drug Interaction.
Lorvas SR Tablet may interact with
lithium, which is used to treat mental disorders. The use of Lorvas SR with
lithium may cause the removal of Lorvas SR through kidneys and add a high risk due to the increased amount of lithium in the blood. The patients should read the leaflet or prescribing information before using these medicines together.
There may be an interaction of
Lorvas SR with
norepinephrine, which is used to treat low blood pressure. When Lorvas SR is used in combination with norepinephrine, may decrease the responsiveness of norepinephrine to blood vessels.
Lorvas SR Tablet interacts with antiarrhythmic drugs, which are used to treat irregular heartbeat. Class Ia antiarrhythmic drugs (
disopyramide,
quinidine,
hydroquinidine) and class III antiarrhythmic drugs (
bretylium,
amiodarone,
sotalol dofetilide,
ibutilide) can cause prolonged heartbeat (Torsade de pointes) in patients with higher risk for the condition of low
potassium levels in the blood. If necessary, check low blood
potassium level and correct it before using this combination. Blood
electrolytes and electrocardiography (ECG) monitoring is also advised. Use such drugs that are not associated with the effect of heartbeat prolongation.
Special instructions need to be followed while taking this medicine along with antipsychotics, which are used to treat mental disorders. The use of Lorvas SR with antipsychotics such as butyrophenones (
haloperidol,
droperidol),
phenothiazines (cyamemazine,
thioridazine,
chlorpromazine,
levomepromazine,
trifluoperazine) and benzamides (
sulpiride,
amisulpride,
tiapride) may cause prolonged heartbeat (Torsade de pointes) in the patients. Low blood
potassium is a risk factor. The combined use of these medicines may also increase the blood pressure lowering effect and thus the risk of sudden fall in the blood pressure increases. The patients should be monitored for changes in blood
potassium levels,
electrolyte level, electrocardiogram before using these medicines together. If low
potassium levels are diagnosed, provide treatment and use alternative medicines which do not cause prolongation of the heartbeat.
Your doctor's guidelines may need to be followed while taking this medicine along with angiotensin converting
enzyme inhibitors, which are used to treat high blood pressure. The patients with narrow kidney arteries or low
sodium level may suffer from a sudden fall in blood pressure or kidney failure while using Lorvas SR with angiotensin converting
enzyme inhibitors. The functioning of kidneys should be monitored during the first few weeks of treatment with an A.C.E inhibitor. In patients with high blood pressure and low
sodium level, stop using Lorvas SR three days before starting treatment with an A.C.E inhibitor. If necessary, then a low initial dose of Lorvas SR with gradual increase afterward is recommended. In patients with heart failure, a low starting dose of Lorvas SR may be prescribed.
Lorvas SR Tablet may interact with non-steroidal anti-inflammatory drugs (systemic route), which are used to treat
fever,
pain and inflammation. These drugs can reduce the blood pressure lowering effect of Lorvas SR. There are also the risk of acute kidney failure in dehydrated patients. While starting the treatment with Lorvas SR,
hydrate the patient and monitor the functioning of the kidneys.
There may be an interaction of
Lorvas SR with medicines lowering
potassium level in the blood. The use of Lorvas SR with drugs lowering the
potassium level in the blood such as stimulant
laxatives, an injection of
amphotericin B in the vein,
tetracosactide, gluco-and mineralocorticoid injection, and digitalis may cause an excessive lowering of
potassium level in the patients. The monitoring and suitable treatment for reduction in potassium level is advised. When using Lorvas SR together with digitalis preparations, monitor electrocardiogram and provide adequate treatment accordingly. The non-stimulant laxatives should be used as an alternate for stimulant laxatives.
Lorvas SR Tablet interacts with
baclofen, which is used to treat muscle spasms. When Lorvas SR is used with baclofen, may increase the blood pressure lowering effect of Lorvas SR. Such patients should remain
hydrated, and the functioning of kidneys should be monitored at start of the treatment.
Special instructions need to be followed while taking this medicine along with potassium-sparing
diuretics (
amiloride,
spironolactone,
triamterene), which are used to treat high blood pressure. The blood
potassium level may be increased or decreased in patients with
diabetes and kidney failure by using these drugs with Lorvas SR. In such cases, blood
potassium level or electrocardiography (ECG) should be monitored. If required, treatment must be reviewed.
Your doctor's guidelines may need to be followed while taking this medicine along with
metformin, which is used to treat
diabetes. The use of Lorvas SR with metformin may result in the build-up of acids in the body (lactic
acidosis) due to the possibility of kidney failure. The use of metformin in patients with kidney dysfunction (
creatinine clearance of more than 15 mg/liter in men and 12 mg/liter in women) is not recommended.
Lorvas SR Tablet may interact with iodinated contrast
media, which is used in diagnostic
imaging tests. During the treatment with large doses of iodinated contrast media, the risk of acute kidney failure is increased in dehydrated patients. Rehydrate the patients before using iodinated compounds.
There may be an interaction of
Lorvas SR with
antidepressants, which are used to treat
depression. The use of Lorvas SR with
imipramine like antidepressants (tricyclics), may enhance the blood pressure lowering effect and thus the risk of a sudden fall in the blood pressure also increases.
Lorvas SR Tablet interacts with
calcium salts, which are used as dietary supplements. The use of Lorvas SR with
calcium salts may cause an increase in the calcium level (
hypercalcemia) resulting from a decrease in the removal of calcium by urine.
Special instructions need to be followed while taking this medicine along with immunosuppressive drugs such as
cyclosporine or
tacrolimus. The combined use of Lorvas SR with immunosuppressive drugs such as
cyclosporine or tacrolimus may increase the
creatinine levels in the blood.
Your doctor's guidelines may need to be followed while taking this medicine along with
corticosteroids, which is used to treat inflammation. The combined use of Lorvas SR with
corticosteroids may cause a decrease in the blood pressure lowering effect of Lorvas SR due to
water/ or
sodium retention.
This page does not contain all the possible interactions of Lorvas SR Tablet. Share a list of all medicines that you use with your doctor and pharmacist. Do not start, stop, or change the dose of any
medicines without the approval of your doctor.